Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Memory Pharmaceuticals Corp. (MEMY) Announces Completion of Phase I Ascending Dose Study to Fight Alzheimer’s

According to the Alzheimer’s Association, approximately 5.2 million Americans are living with Alzheimer’s. Someone develops Alzheimer’s every 71 seconds, and it is the sixth-leading cause of death. To fight the mental, physical and emotional devastation this disease causes individuals, family and friends, Memory Pharmaceuticals Corp. (Nasdaq: MEMY) is focused on developing innovative drugs for the treatment of debilitating CNS disorders that may impair memory and other cognitive functions, including Alzheimer’s disease and schizophrenia.

The company today announced the completion of its phase I multiple ascending dose study of R4996/MEM 63908. The study is the fourth and final study involving health volunteers to determine the efficacy of the nicotinic alpha-7 receptor being developed in collaboration with Roche.

Per the agreement, Memory Pharmaceuticals is responsible for conducting the clinical trials, while Roche is responsible for later-stage development and commercialization.

“We conducted a robust and comprehensive phase 1 program for R4996/MEM 63908, during which over 100 volunteers took R4996/MEM 63908. The data from these studies will provide us and our partner Roche with important insights into the safety, dosing and appropriate development path for the compound,” Stephen Murray, M.D., Ph.D., chief medical officer of Memory Pharmaceuticals, stated in the press release. “R4996/MEM 63908, the second compound in our nicotinic alpha-7 receptor program, has the potential to address serious cognitive disorders such as Alzheimer’s disease, and we look forward to analyzing the data from these studies.”

The study included a randomized, double-blind, placebo-controlled single ascending dose study in 56 healthy adult male volunteers; a food interaction study in 12 healthy adult male volunteers; a randomized, placebo-controlled single dose study in 16 elderly male and female volunteers; and a randomized, placebo-controlled multiple ascending dose study in 48 healthy volunteers, which included 32 young males and females and 16 elderly males and females.

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *